Sanofi Genzyme News |

Featured Press Releases

October 19, 2018
FDA approves asthma indication for Dupixent® (dupilumab)
The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
October 19, 2018
Kevzara® (sarilumab) data at the 2018 ACR/ARHP Annual Meeting provide additional insight on safety, efficacy in rheumatoid arthritis
Data from analyses of the Kevzara® (sarilumab) Phase 3 clinical development program will be presented at the 2018 ACR/ARHP Annual Meeting, which is being held in Chicago from October 19 to 24.
October 16, 2018
Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
Two pivotal Phase 3 placebo-controlled trials evaluating Dupixent® (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps (“CRSwNP”) met all primary and secondary endpoints.
October 10, 2018
Sanofi Presents 8-Year Data on Lemtrada® (Alemtuzumab)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Patients with relapsing remitting multiple sclerosis who received Sanofi’s Lemtrada® (alemtuzumab) continued to experience effects of treatment on disease activity through eight years, according to extension data of two Phase 3 studies. These results...

Leadership

Bill Sibold
Executive Vice President and Head of Sanofi Genzyme
Bill joined Sanofi Genzyme in 2011 as Senior Vice President and Head of Multiple Sclerosis, and oversaw the successful launches of its two MS treatments. As Head of Sanofi Genzyme, he leads the business’s efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology. More...

Tweets

During #EczemaAwarenessMonth, learn about #atopicdermatitis and how it impacts the lives of those who have it:… https://t.co/yeLHZbRuH7-5 hours 23 min ago

Our CEO, Dr. Olivier Brandicourt, shares his perspective on the significance of this week's FDA approval for those… https://t.co/Ieem4wm5fm-8 hours 8 sec ago

#DYK high interleukin-6 (IL-6) levels have been found in patients with fatigue, a common symptom in patients with R… https://t.co/hsXDEVlkYU-8 hours 17 min ago

#DYK 40%-50% of people with RA have high levels of interleukin-6, also known as IL-6? Follow us this week as we ex… https://t.co/13NfIkRDls-1 day 7 hours ago

We’re committed to research in advanced cutaneous squamous cell #carcinoma (CSCC), with new data (abstract #1292P)… https://t.co/QQsvnr3PtD-1 day 13 hours ago

Search Newsroom

Featured Press Releases

Featured Videos

Leadership

Media Resources

Tweets

Social Media